Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases

Abstract

Emerging viruses such as HIV, dengue, influenza A, SARS coronavirus, Ebola, and other viruses pose a significant threat to human health. Majority of these viruses are responsible for the outbreaks of pathogenic lethal infections. To date, there are no effective therapeutic strategies available for the prophylaxis and treatment of these infections. Chloroquine analogs have been used for decades as the primary and most successful drugs against malaria. Concomitant with the emergence of chloroquine-resistant Plasmodium strains and a subsequent decrease in the use as antimalarial drugs, other applications of the analogs have been investigated. Since the analogs have interesting biochemical properties, these drugs are found to be effective against a wide variety of viral infections. As antiviral action, the analogs have been shown to inhibit acidification of endosome during the events of replication and infection. Moreover, immunomodulatory effects of analogs have been beneficial to patients with severe inflammatory complications of several viral diseases. Interestingly, one of the successful targeting strategies is the inhibition of HIV replication by the analogs in vitro which are being tested in several clinical trials. This review focuses on the potentialities of chloroquine analogs for the treatment of endosomal low pH dependent emerging viral diseases.

Cited by papers we hold 7

• Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19 · 2021
  Not checked
• COVID-19 Therapeutic Options Under Investigation · 2020
  Not checked
• The Use of Antimalarial Drugs against Viral Infection · 2020
  Not checked
• Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 · 2020
  No notice
• The hallmarks of COVID-19 disease · 2020
  No notice
• Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs · 2020
  No notice
• Hydroxychloroquine in rheumatic autoimmune disorders and beyond · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.